

104TH CONGRESS
1ST SESSION

H. R. 1078

To amend title XVIII of the Social Security Act to provide for coverage of beta interferons approved by the FDA for self-administration for treatment of multiple sclerosis under the Medicare program, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

FEBRUARY 28, 1995

Mr. LAFALCE introduced the following bill; which was referred to the Committee on Commerce and, in addition, to the Committees on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To amend title XVIII of the Social Security Act to provide for coverage of beta interferons approved by the FDA for self-administration for treatment of multiple sclerosis under the Medicare program, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Multiple Sclerosis
5 Home Treatment Act of 1995”.

1 **SEC. 2. COVERAGE AND PAYMENT OF SELF-ADMINISTERED**
2 **BETASERON UNDER MEDICARE.**

3 Section 1861(s)(2) of the Social Security Act (42
4 U.S.C. 1395x(s)(2)) is amended—

5 (1) By striking “and” at the end of subpara-
6 graph (P);

7 (2) By striking the period at the end of sub-
8 paragraph (Q) and adding in lieu thereof, “; and”;
9 and

10 (3) By adding at the end the following new sub-
11 paragraph:

12 “(R) beta interferons approved by the Food and
13 Drug Administration (FDA) for self-administration
14 by patients with multiple sclerosis competent to use
15 such biological without medical supervision with re-
16 spect to the administration of such biological, sub-
17 ject to methods and standards established by the
18 Secretary by regulation for the safe and effective use
19 of beta interferons.”

20 **SEC. 3. REGULATIONS.**

21 The Secretary of Health and Human Services shall
22 issue final regulations setting forth standards and meth-
23 ods for safe and effective use of beta interferons for pur-
24 poses of payments under section 2 of this Act. The Sec-
25 retary shall issue such regulations not later than 150 days
26 after the date of enactment of this Act for any beta

1 interferon approved by the FDA on or before the date of
2 enactment of this Act, and not later than 60 days after
3 the date of approval for any beta interferon approved by
4 the FDA after the date of enactment of this Act.

5 **SEC. 4. EFFECTIVE DATE.**

6 The amendments made by section 2 of this Act shall
7 apply to payments for items and services furnished on or
8 after October 1, 1995.

○